[Long-term antihypertensive therapy with moxonidine (cynt) in patients with insulin-independent diabetes mellitus].
Lazebnik
L B
LB
Malichenko
S B
SB
Serebrov
A N
AN
D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000503:physiopathology / Q000523:psychology; D004232:Diuretics; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D007093:Imidazoles / Q000009:adverse effects / Q000819:agonists* / Q000627:therapeutic use*; D054755:Imidazoline Receptors; D008297:Male; D008875:Middle Aged; D011955:Receptors, Drug / Q000819:agonists*; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D013997:Time Factors
D000959:Antihypertensive Agents; D004232:Diuretics; D007093:Imidazoles; D054755:Imidazoline Receptors; D011955:Receptors, Drug; D049993:Sodium Chloride Symporter Inhibitors; D006852:Hydrochlorothiazide; C043482:moxonidine